Skip to main content
NASDAQ:ZSAN

Zosano Pharma Stock Forecast, Price & News

$0.74
+0.04 (+5.01 %)
(As of 05/14/2021 02:23 PM ET)
Add
Compare
Today's Range
$0.71
$0.75
50-Day Range
$0.74
$1.27
52-Week Range
$0.33
$3.06
Volume17,436 shs
Average Volume8.51 million shs
Market Capitalization$78.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.98
30 days | 90 days | 365 days | Advanced Chart
Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter.


Zosano Pharma logo

About Zosano Pharma

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZSAN
CUSIPN/A
Phone510-745-1200
Employees45
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$0.40 per share

Profitability

Net Income$-37,590,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$78.69 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.41 out of 5 stars

Medical Sector

694th out of 2,039 stocks

Pharmaceutical Preparations Industry

324th out of 769 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

Is Zosano Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zosano Pharma stock.
View analyst ratings for Zosano Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Zosano Pharma?

Wall Street analysts have given Zosano Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zosano Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Zosano Pharma
.

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) issued its quarterly earnings results on Wednesday, May, 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.08).
View Zosano Pharma's earnings history
.

How has Zosano Pharma's stock price been impacted by Coronavirus (COVID-19)?

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZSAN stock has increased by 29.2% and is now trading at $0.7315.
View which stocks have been most impacted by COVID-19
.

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Zosano Pharma's stock reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ZSAN?

3 brokers have issued 12 month price targets for Zosano Pharma's shares. Their forecasts range from $2.00 to $2.50. On average, they expect Zosano Pharma's share price to reach $2.17 in the next twelve months. This suggests a possible upside of 196.2% from the stock's current price.
View analysts' price targets for Zosano Pharma
or view top-rated stocks among Wall Street analysts.

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the following people:
  • Mr. Steven Lo, Pres, CEO & Director (Age 54, Pay $155.67k)
  • Dr. Donald J. Kellerman, VP of Clinical Devel. & Medical Affairs (Age 66, Pay $353k)
  • Ms. Christine Matthews, Chief Financial Officer (Age 53)
  • Ms. Hayley Lewis, Sr. VP of Operations (Age 45)
  • Jeffrey L. Quillen, Sec.

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering (IPO) on Tuesday, January 27th 2015. The company issued 4,300,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners acted as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.27%), Geode Capital Management LLC (0.76%), Northern Trust Corp (0.19%), Barclays PLC (0.14%), GSA Capital Partners LLP (0.08%) and Bank of New York Mellon Corp (0.04%).
View institutional ownership trends for Zosano Pharma
.

Which major investors are selling Zosano Pharma stock?

ZSAN stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, and Wealthcare Advisory Partners LLC.
View insider buying and selling activity for Zosano Pharma
or view top insider-selling stocks.

Which major investors are buying Zosano Pharma stock?

ZSAN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Barclays PLC, Northern Trust Corp, and Bank of New York Mellon Corp.
View insider buying and selling activity for Zosano Pharma
or or view top insider-buying stocks.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $0.73.

How much money does Zosano Pharma make?

Zosano Pharma has a market capitalization of $78.07 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.

How many employees does Zosano Pharma have?

Zosano Pharma employs 45 workers across the globe.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is www.zosanopharma.com.

Where are Zosano Pharma's headquarters?

Zosano Pharma is headquartered at 34790 ARDENTECH COURT, FREMONT CA, 94555.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.